• Scandinavian Medical Solutions cut FY 2025/26 guidance; revenue seen at DKK 155-175 million, down from DKK 190-220 million.
• EBITDA now forecast at DKK -9 to -13 million, versus the prior outlook of DKK 0-5 million.
• Revision reflects tougher price competition, elevated freight costs, stricter dangerous-goods transport rules, US tariffs, geopolitical uncertainty.
• Accelerated inventory actions to reduce stock, lift turnover, release working capital; full impact expected by the FY 2026/27 half-year.
• Guidance follows an April 1, 2026 downgrade from revenue DKK 220-250 million and EBITDA DKK 11-15 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scandinavian Medical Solutions A/S published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.